Skip to main content
Evidence-Based Supplement Research
Evidence-Based Supplement Research

Vitamin C and Reduced Tumor Necrosis Factor Alpha

Research synthesisLow evidenceMixed effect size5 studies · 2 beneficial · 3 neutral · 0 harmful

Across 5 studies, 2 reported beneficial moderate-sized effects of Vitamin C on reducing tumor necrosis factor-alpha (TNF-α), while 3 studies found neutral effects. The predominant effect size is mixed, as only a minority of studies showed benefit. The median study duration was 42 days, and the most-studied dose range was 250-1000 mg/day, primarily in clinical populations (e.g., septic shock patients, hemodialysis patients, older women with sarcopenia).

  • Effective dose range: 250-1000 mg/day
  • Studied populations: clinical populations (septic shock patients, hemodialysis patients, older women with sarcopenia) and healthy young males

Caveats: Many of the included studies did not reach statistical significance — effect may be smaller than the predominant direction suggests. Evidence base is small (only 5 studies) — conclusions should be considered preliminary. Two studies showing benefit were in acute/severe clinical settings (sepsis), while studies in chronic conditions (hemodialysis, sarcopenia) showed no effect, suggesting benefits may be context-dependent.

Generated Jul 14, 2026
Doses used in studies
  • mg/day: 250–1,000 (median 625, IQR 437.5812.5) 2 studies
  • IU/day: 60,000 (median 60,000, IQR 60,00060,000) 1 study
  • g/day: 1 (median 1, IQR 11) 1 study
Time to effect
Median: 6 weeks · IQR 3.3 weeks9 weeks · Range 7 days2.8 months — Reported in 4 of 5 studies
Safety in these studies
5 of 5 papers
Back to top